ClinVar Miner

Submissions for variant NM_001271208.2(NEB):c.61G>A (p.Glu21Lys) (rs199907781)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000733851 SCV000617818 uncertain significance not provided 2017-10-19 criteria provided, single submitter clinical testing The c.61 G>A variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The c.61 G>A variant is observed in 20/126,456 (0.02%) alleles from individuals of European background (Lek et al., 2016). Multiple in-silico splice prediction models predict that c.61 G>A enhances a cryptic splice donor site which may supplant the natural donor site and lead to abnormal gene splicing. However, in the absence of RNA/functional studies the actual effect of c.61 G>A on splicing in this individual is unknown. If c.61 G>A does not alter splicing, it will result in the E21K missense change. The E21K variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved in mammals. However, most reported pathogenic variants in the NEB gene are truncating/loss-of-function. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function.
Invitae RCV000550343 SCV000640840 uncertain significance Nemaline myopathy 2 2019-10-24 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid with lysine at codon 21 of the NEB protein (p.Glu21Lys). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is present in population databases (rs199907781, ExAC 0.01%). This variant has not been reported in the literature in individuals with NEB-related disease. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000733851 SCV000861952 uncertain significance not provided 2018-06-13 criteria provided, single submitter clinical testing
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology RCV000550343 SCV000993627 uncertain significance Nemaline myopathy 2 2019-03-15 criteria provided, single submitter research
Natera, Inc. RCV000550343 SCV001458316 uncertain significance Nemaline myopathy 2 2020-01-17 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.